The real drug development delay? Bad communication.

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of ...

In 2026, the biotech landscape has undergone a seismic shift, moving beyond the hype cycles of the past decade into a phase of tangible, life-saving applications. With the first wave of CRISPR-based ...

Gene editing, AI-driven drug discovery, and multi-omics integration are converging with new FDA regulatory pathways to bring precision therapies to market faster. These advances, supported by a ...

AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this ...

Healthcare veteran Dr Douglas Williams discusses the impact of recent political upheaval in the US and the prospect of major ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong ...

NEW YORK--(BUSINESS WIRE)--AV Laboratories is redefining the future of skincare by translating decades of advanced biotechnology research into clinically driven formulations designed for everyday use.

Discover Prague's biotech hub, now viewed as the primary ‘entry gateway’ into the wider Central and Eastern European ...